Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a revised press release dated July 26, 2025, titled "Revised Press Release for Unaudited Financial results for the quarter ended June 30, 2025".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals filed a revised investor presentation for Q1FY26 results, correcting an inadvertent error on pages 10 and 11 of the earlier version. The company reported a strong quarter with revenue up 23.1% year-on-year to ₹756 Mn, driven by sustained performance across key brands. Operating EBITDA grew 24.1% to ₹157 Mn with margins expanding to 20.8%, while net profit more than doubled to ₹108 Mn with PAT margin rising 562 basis points to 14.3%. The company added ₹153 Mn of free cash during the quarter, taking its cash balance to ₹1,609 Mn as of June 30, 2025, and strengthened its ranking to #7 in the Gynae CVM segment. Management has guided for 15%+ revenue growth and 20%+ operating EBITDA improvement in FY26, with 12-14% revenue growth and 100-150 basis points margin expansion targeted beyond FY26, alongside a stated intent to pursue a strategic inorganic opportunity using its cash reserves.
Strong Q1 performance with doubled profits, expanding margins, and a healthy zero-debt cash pile of ₹1,609 Mn positions the stock positively. Multiyear revenue and margin guidance, combined with potential acquisition plans, could support investor sentiment and drive upside if execution continues.